STOCK TITAN

[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

ANI Pharmaceuticals (ANIP) reported an insider transaction on a Form 4. Senior Vice President, General Counsel & Secretary Meredith W. Cook sold 400 shares of common stock on 10/13/2025 at $90.09 per share under a Rule 10b5-1 trading plan adopted on September 17, 2024.

Following the sale, Cook beneficially owns 75,674 shares, held directly. This filing reflects routine insider activity disclosed for transparency.

ANI Pharmaceuticals (ANIP) ha riferito una transazione interna su un Form 4. Meredith W. Cook, Senior Vice President, General Counsel & Secretary, ha venduto 400 azioni ordinarie il 13/10/2025 a 90,09 USD per azione nell'ambito di un piano di trading Rule 10b5-1 adottato il 17 settembre 2024.

Dopo la vendita, Cook detiene direttamente 75.674 azioni in modo benefico. Questo deposito riflette l'attività interna di routine divulgata per la trasparenza.

ANI Pharmaceuticals (ANIP) informó una operación de insider en un Form 4. Meredith W. Cook, vicepresidenta senior, consejera general y secretaria, vendió 400 acciones ordinarias el 13/10/2025 a 90,09 USD por acción bajo un plan de negociación Rule 10b5-1 adoptado el 17 de septiembre de 2024.

Después de la venta, Cook posee de forma beneficiosa 75.674 acciones, mantenidas directamente. Este escrito refleja la actividad interna rutinaria divulgada para la transparencia.

ANI Pharmaceuticals (ANIP)이 Form 4에 따른 내부자 거래를 보고했습니다. 수석 부사장 겸 총괄 고문 및 비서 Meredith W. Cook은 2024년 9월 17일에 채택된 Rule 10b5-1 거래 계획에 따라 2025년 10월 13일 주당 90.09달러로 보통주 400주를 매도했습니다.

매도 후 Cook은 직접 보유한 75,674주를 유익하게 소유합니다. 이 공시는 투명성을 위한 일상적인 내부자 활동을 반영합니다.

ANI Pharmaceuticals (ANIP) a signalé une opération interne sur un formulaire Form 4. Meredith W. Cook, vice-présidente principale, conseillère générale et secrétaire, a vendu 400 actions ordinaires le 13/10/2025 à 90,09 USD par action dans le cadre d'un plan de trading Rule 10b5-1 adopté le 17 septembre 2024.

Suite à la vente, Cook détient directement 75 674 actions en sa qualité bénéficiaire. Ce dépôt reflète une activité interne de routine divulguée pour la transparence.

ANI Pharmaceuticals (ANIP) meldete eine Insider-Transaktion im Formular 4. Meredith W. Cook, Senior Vice President, General Counsel & Secretary, verkaufte am 13.10.2025 400 Stammaktien zu 90,09 USD pro Aktie im Rahmen eines Rule 10b5-1-Handelplans, der am 17.09.2024 beschlossen wurde.

Nach dem Verkauf besitzt Cook weiterhin 75.674 Aktien direkt. Dieses Filing spiegelt routinemäßige Insider-Tätigkeiten zur Transparenz wider.

أبلغت ANI Pharmaceuticals (ANIP) عن معاملة داخلية بموجب نموذج 4. بعتت ميريذيث دبليو. كوك، نائبة الرئيس الأول، المستشارة العامة والأمين، 400 سهم عادي في 13/10/2025 بسعر 90.09 دولار للسهم بموجب خطة تداول Rule 10b5-1 المعتمدة في 17 سبتمبر 2024.

بعد البيع، تملك كوك بشكل مستفيد 75,674 سهماً، محفوظة مباشرة. يعكس هذا الإخطار نشاطاً داخلياً روتينياً من أجل الشفافية.

ANI Pharmaceuticals (ANIP) 在 Form 4 上披露了一笔内部人交易。高级副总裁、总法律顾问兼秘书 Meredith W. Cook 于 2025/10/13 以每股 90.09 美元出售了 400 股普通股,依据于 2024/09/17 通过的 Rule 10b5-1 交易计划。

销售后,Cook 直接持有 75,674 股,以受益所有权方式拥有。该备案反映了为透明而披露的日常内部人活动。

Positive
  • None.
Negative
  • None.

ANI Pharmaceuticals (ANIP) ha riferito una transazione interna su un Form 4. Meredith W. Cook, Senior Vice President, General Counsel & Secretary, ha venduto 400 azioni ordinarie il 13/10/2025 a 90,09 USD per azione nell'ambito di un piano di trading Rule 10b5-1 adottato il 17 settembre 2024.

Dopo la vendita, Cook detiene direttamente 75.674 azioni in modo benefico. Questo deposito riflette l'attività interna di routine divulgata per la trasparenza.

ANI Pharmaceuticals (ANIP) informó una operación de insider en un Form 4. Meredith W. Cook, vicepresidenta senior, consejera general y secretaria, vendió 400 acciones ordinarias el 13/10/2025 a 90,09 USD por acción bajo un plan de negociación Rule 10b5-1 adoptado el 17 de septiembre de 2024.

Después de la venta, Cook posee de forma beneficiosa 75.674 acciones, mantenidas directamente. Este escrito refleja la actividad interna rutinaria divulgada para la transparencia.

ANI Pharmaceuticals (ANIP)이 Form 4에 따른 내부자 거래를 보고했습니다. 수석 부사장 겸 총괄 고문 및 비서 Meredith W. Cook은 2024년 9월 17일에 채택된 Rule 10b5-1 거래 계획에 따라 2025년 10월 13일 주당 90.09달러로 보통주 400주를 매도했습니다.

매도 후 Cook은 직접 보유한 75,674주를 유익하게 소유합니다. 이 공시는 투명성을 위한 일상적인 내부자 활동을 반영합니다.

ANI Pharmaceuticals (ANIP) a signalé une opération interne sur un formulaire Form 4. Meredith W. Cook, vice-présidente principale, conseillère générale et secrétaire, a vendu 400 actions ordinaires le 13/10/2025 à 90,09 USD par action dans le cadre d'un plan de trading Rule 10b5-1 adopté le 17 septembre 2024.

Suite à la vente, Cook détient directement 75 674 actions en sa qualité bénéficiaire. Ce dépôt reflète une activité interne de routine divulguée pour la transparence.

ANI Pharmaceuticals (ANIP) meldete eine Insider-Transaktion im Formular 4. Meredith W. Cook, Senior Vice President, General Counsel & Secretary, verkaufte am 13.10.2025 400 Stammaktien zu 90,09 USD pro Aktie im Rahmen eines Rule 10b5-1-Handelplans, der am 17.09.2024 beschlossen wurde.

Nach dem Verkauf besitzt Cook weiterhin 75.674 Aktien direkt. Dieses Filing spiegelt routinemäßige Insider-Tätigkeiten zur Transparenz wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Cook Meredith

(Last) (First) (Middle)
C/O ANI PHARMACEUTICALS, INC.
210 MAIN STREET WEST

(Street)
BAUDETTE MN 56623

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SR. VP, GENERAL COUNSEL & SEC.
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/13/2025 S(1) 400 D $90.09 75,674 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.
Remarks:
/s/ Meredith W. Cook 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANIP report?

A Form 4 disclosed that Meredith W. Cook sold 400 shares of common stock.

At what price were the ANIP shares sold?

The shares were sold at $90.09 per share.

When did the ANIP insider sale occur?

The transaction date was 10/13/2025.

How many ANIP shares does the insider own after the sale?

Following the sale, the insider beneficially owns 75,674 shares, held directly.

Who is the ANIP insider involved in this Form 4?

Senior Vice President, General Counsel & Secretary Meredith W. Cook.

Was the ANIP sale under a 10b5-1 plan?

Yes. It was effected pursuant to a Rule 10b5-1 trading plan adopted on September 17, 2024.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

1.98B
18.36M
10.42%
97.8%
9.42%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE